Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB501230145

Publication Date:

January 20, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
Highlights
The global Castrate Resistant Prostate Cancer Therapeutics market was valued at US$ 17070 million in 2022 and is anticipated to reach US$ 32320 million by 2029, witnessing a CAGR of 11.2% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Castrate Resistant Prostate Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics.
The Castrate Resistant Prostate Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Castrate Resistant Prostate Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castrate Resistant Prostate Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Segment by Type
Hormonal Therapy
Chemotherapy
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hormonal Therapy
1.2.3 Chemotherapy
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region
2.2.1 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Dynamics
2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
2.3.2 Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Drivers
2.3.3 Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Challenges
2.3.4 Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue
3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue
3.4 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2022
3.5 Castrate Resistant Prostate Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Castrate Resistant Prostate Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Castrate Resistant Prostate Cancer Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type
4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application
5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer/Astellas (Xtandi)
11.1.1 Pfizer/Astellas (Xtandi) Company Detail
11.1.2 Pfizer/Astellas (Xtandi) Business Overview
11.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.1.4 Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.1.5 Pfizer/Astellas (Xtandi) Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 AstraZeneca/Merck (Lynparza)
11.3.1 AstraZeneca/Merck (Lynparza) Company Detail
11.3.2 AstraZeneca/Merck (Lynparza) Business Overview
11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.3.5 AstraZeneca/Merck (Lynparza) Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction
11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.4.5 Bayer Recent Development
11.5 Jiangsu Hengrui Pharmaceuticals
11.5.1 Jiangsu Hengrui Pharmaceuticals Company Detail
11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction
11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.6 CTTQ
11.6.1 CTTQ Company Detail
11.6.2 CTTQ Business Overview
11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction
11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.6.5 CTTQ Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction
11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 Hansoh
11.8.1 Hansoh Company Detail
11.8.2 Hansoh Business Overview
11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction
11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.8.5 Hansoh Recent Development
11.9 Clovis Oncology
11.9.1 Clovis Oncology Company Detail
11.9.2 Clovis Oncology Business Overview
11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction
11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.9.5 Clovis Oncology Recent Development
11.10 Zhendong Pharmaceutical
11.10.1 Zhendong Pharmaceutical Company Detail
11.10.2 Zhendong Pharmaceutical Business Overview
11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction
11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2018-2023)
11.10.5 Zhendong Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.